Cdsco Finds D Cold Total, Combiflam To Be Substandard
Dt.24/04/2017
The Central Drugs Standard Control Organization (CDSCO) has found popular painkiller Combiflam and cold medicine D Cold Total, manufactured and sold by Sanofi India and Reckitt Benckiser Healthcare India, respectively, to be substandard in its tests done last month. Moreover, Cipla’s Oflox-100 DT tablets and Theo Asthalin tablets, as well as Cadila’s Cadilose solution have also been found to be substandard. In total, the CDSCO has issued a drug alert for 60 medicines, including five aforementioned drugs, as they failed different quality tests in March 2017. Combiflam batch number A151195, manufactured in October, 2015, failed the disintegration test of CDSCO. In last year, the CDSCO had found Combiflam to be substandard three times — in February, April and June — for failing the same disintegration test. Sanofi India spokesperson said: “Certain batches of Combiflam manufactured in 2015 were deemed substandard because the tablets showed a delay in the disintegration time. Essentially, there are several pharmaceutical parameters that are routinely assessed, one of which is to check the breakdown of a tablet in the human body. The batch identified by the CDSCO in March 2017 was also manufactured in 2015. Once we receive the official notice, we will ascertain the finding and take appropriate action.”